NYSE$CTEV

Claritev Corp · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

MultiPlan's Q3 2022 financial performance was impacted by decreased revenues and net income due to lower patient utilization of healthcare services.

MultiPlan reported Q3 2022 revenues of $250.5 million, a decrease of 13.1% compared to Q3 2021. Net income decreased by 74.8% to $19.7 million, and Adjusted EBITDA decreased by 21.2% to $172.2 million. The decline was primarily attributed to lower volumes and an unfavorable mix of identified potential medical cost savings.

  • Revenues for Q3 2022 were $250.5 million, a 13.1% decrease compared to Q3 2021.
  • Net income for Q3 2022 was $19.7 million, a 74.8% decrease compared to Q3 2021.
  • Adjusted EBITDA for Q3 2022 was $172.2 million, a 21.2% decrease compared to Q3 2021.
  • Free Cash Flow for Q3 2022 was $88.2 million, compared to $146.6 million for Q3 2021.

Headline financials

Total Revenue

$250M

Previous: $288M-13.1%
EPS (adj)

$1.20

Previous: $5.60-78.6%
Capital Expenditures

-$64.2M

Previous: $20.4M-414.6%
Free Cash Flow

$280M

Previous: $147M+91.3%
Net Income

$19.7M

Previous: $78.2M-74.8%
Operating Income

$36.4M

Previous: $104M-65.2%
Gross Profit

-$53M

Previous: $244M-121.8%
Cash & Equivalents

$439M

Previous: $225M+95.0%
Total Assets

$8.19B

Previous: $8.28B-1.0%
Stock-Based Comp

$4.06M

Previous: $4.75M-14.5%

Revenue & EPS history

Multiplan · Revenue · Quarterly

$250M

Q3 2022-13.1%vs Q3 2021
Beat estimate in 9 of 13 quarters(69%)
ActualEstimate

Forward guidance

MultiPlan updated its Full Year 2022 guidance, anticipating revenues between $1,075 million and $1,090 million and Adjusted EBITDA between $765 million and $780 million. The company expects Q4 2022 revenues between $235 million and $250 million and Adjusted EBITDA between $155 million and $170 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

-6.5%

Avg return

Earnings day

-5.1%

Avg return

5 days after

-3.8%

Avg return

30 days after

36%

9 / 25 earnings

Positive

+20.8%

Q1 2021

Best reaction

-32.8%

Q4 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-8.8%+7.7%-2.6%
Q4 2025-31.8%-42.0%-31.4%
Q3 2025+11.8%-5.4%-45.2%
Q1 2025+4.2%+7.5%+95.1%
Q4 2024-32.8%-28.1%-24.8%
Q3 2024-6.5%-3.4%-22.6%
Q2 2024-23.9%-10.2%-47.8%
Q1 2024+10.9%-1.5%-36.6%
Q4 2023-0.9%-13.4%-27.6%
Q3 2023-6.5%-9.7%-14.3%
Q2 2023-8.9%-14.0%-17.8%
Q1 2023-5.4%+21.0%+97.6%
Q4 2022-10.2%+10.0%+6.0%
Q3 2022-27.8%-18.3%-31.1%
Q2 2022-12.4%-13.4%-33.1%
Q1 2022+1.0%+18.4%+27.4%
Q4 2021-8.0%-18.9%-14.4%
Q3 2021+0.2%-11.0%-4.3%
Q2 2021-6.2%-10.5%-20.6%
Q1 2021+20.8%+27.0%+45.5%
Q2 2020+0.5%-0.2%+1.9%
Q4 2020-18.6%-20.3%-19.7%
Q3 2020-4.6%+0.7%+20.8%
Q1 2020+0.5%+0.7%+2.3%
Q4 2019+0.5%+0.7%+2.3%
Q3 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro